Skip to Main Content

Table 3. Bleeding, Thrombocytopenia, and Blood Transfusion in Trials (> 400 Patients)

* TIMI criteria for major bleeding = intracranial hemorrhage or a decrease in hemoglobin of greater than 5 g/dl.

† Not including bleeding during coronary arterial bypass graft surgery.

‡ Stated in article as “blood products.”

§ Erythrocytes and platelets (includes bleeding during coronary artery bypass graft surgery).

∥ Only patients receiving more than 2 units of blood.

EPIC = Evaluation of GPIIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications; EPILOG = Evaluation in PTCA to Improve Long-term Outcome with GPIIb/IIIa Blockade; CAPTURE = Chimeric Antiplatelet Therapy in Unstable Angina Refractory to Standard Medical Therapy; RAPPORT = ReoPro and Primary PTCA Organization and Randomized Trial; EPISTENT = Evaluation of Platelet GPIIb/IIIa Inhibitor for Stenting; TIMI-14 = Thrombolysis in Myocardial Infarction 14; IMPACT-II = Integrlin to Minimize Platelet Aggregation and Coronary Thrombosis II; PURSUIT = Platelet GPIIb/IIIa in Unstable Angina Receptor Suppression Using Integrelin Therapy; RESTORE = Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis; PRISM = Platelet Receptor Inhibition in Ischemic Syndrome Management; PARAGON = Platelet GPIIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network; SYMPHONY = Sibrafiban versus  Aspirin to Yield Maximum Protection from Ischemic Heart Events Post Acute Coronary Syndromes; OPUS = Orofiban in Patients with Unstable Coronary Syndromes; EXCITE = Evaluation of Xemilofiban in Controlling Thrombotic Events; heparin (std) = initial bolus of 100 U/kg heparin before interventional procedure, with additional weight-adjusted boluses to achieve and maintain an activated clotting time greater than 300 s.

Table 3. Bleeding, Thrombocytopenia, and Blood Transfusion in Trials (> 400 Patients)
Table 3. Bleeding, Thrombocytopenia, and Blood Transfusion in Trials (> 400 Patients)
Close Modal

or Create an Account

Close Modal
Close Modal